Literature DB >> 21185796

Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching.

Mario Angelico1, Umberto Cillo, Stefano Fagiuoli, Antonio Gasbarrini, Caius Gavrila, Tania Marianelli, Alessandro Nanni Costa, Alessandra Nardi, Mario Strazzabosco, Patrizia Burra, Salvatore Agnes, Umberto Baccarani, Fulvio Calise, Michele Colledan, Oreste Cuomo, Luciano De Carlis, Matteo Donataccio, Giuseppe M Ettorre, Giorgio E Gerunda, Bruno Gridelli, Luigi Lupo, Vincenzo Mazzaferro, Antonio Pinna, Andrea Risaliti, Mauro Salizzoni, Giuseppe Tisone, Umberto Valente, Giorgio Rossi, Massimo Rossi, Fausto Zamboni.   

Abstract

BACKGROUND: The Liver Match is an observational cohort study that prospectively enrolled liver transplantations performed at 20 out of 21 Italian Transplant Centres between June 2007 and May 2009. Aim of the study is to investigate the impact of donor/recipient matching on outcomes. In this report we describe the study methodology and provide a cross-sectional description of donor and recipient characteristics and of graft allocation.
METHODS: Adult primary transplants performed with deceased heart-beating donors were included. Relevant information on donors and recipients, organ procurement and allocation were prospectively entered in an ad hoc database within the National Transplant Centre web-based Network. Data were blindly analysed by an independent Biostatistical Board.
RESULTS: The study enrolled 1530 donor/recipient matches. Median donor age was 56 years. Female donors (n = 681, median 58, range 12-92 years) were older than males (n = 849, median 53, range 2-97 years, p < 0.0001). Donors older than 60 years were 42.2%, including 4.2% octogenarians. Brain death was due to non-traumatic causes in 1126 (73.6%) cases. Half of the donor population was overweight, 10.1% was obese and 7.6% diabetic. Hepatitis B core antibody (HBcAb) was present in 245 (16.0%) donors. The median Donor Risk Index (DRI) was 1.57 (>1.7 in 35.8%). The median cold ischaemia time was 7.3h (≥ 10 in 10.6%). Median age of recipients was 54 years, and 77.7% were males. Hepatocellular carcinoma (HCC) was the most frequent indication overall (44.4%), being a coindication in roughly 1/3 of cases, followed by viral cirrhosis without HCC (28.2%) and alcoholic cirrhosis without HCC (10.2%). Hepatitis C virus infection (with or without HCC) was the most frequent etiologic factor (45.9% of the whole population and 71.4% of viral-related cirrhosis), yet hepatitis B virus infection accounted for 28.6% of viral-related cirrhosis, and HBcAb positivity was found in 49.7% of recipients. The median Model for End Stage Liver Disease (MELD) at transplant was 12 in patients with HCC and 18 in those without. Multivariate analysis showed a slight but significant inverse association between DRI and MELD at transplant.
CONCLUSIONS: The deceased donor population in Italy has a high-risk profile compared to other countries, mainly due to older donor age. Almost half of the grafts are transplanted in recipients with HCC. Higher risk donors tend to be preferentially allocated to recipients with HCC, who are usually less ill and older. No other relevant allocation strategy is currently adopted at national level.
Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21185796     DOI: 10.1016/j.dld.2010.11.002

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  14 in total

Review 1.  Transplant benefit for patients with hepatocellular carcinoma.

Authors:  Alessandro Vitale; Michael Volk; Umberto Cillo
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Results of a newborn liver transplant program in the era of piggyback technique and extended donor criteria in Italy.

Authors:  Giuseppe Maria Ettorre; Roberto Santoro; Giovanni Vennarecci; Pasquale Lepiane; Mario Antonini; Eugenio Santoro
Journal:  Updates Surg       Date:  2011-07-19

3.  Donor factors similarly impact survival outcome after liver transplantation in hepatocellular carcinoma and non-hepatocellular carcinoma patients.

Authors:  Reena J Salgia; Nathan P Goodrich; Jorge A Marrero; Michael L Volk
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

4.  Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.

Authors:  P A Cortesi; L G Mantovani; A Ciaccio; M Rota; C Mazzarelli; G Cesana; M Strazzabosco; L S Belli
Journal:  Am J Transplant       Date:  2015-07       Impact factor: 8.086

5.  Liver transplantation in adults: Choosing the appropriate timing.

Authors:  Maria Siciliano; Lucia Parlati; Federica Maldarelli; Massimo Rossi; Stefano Ginanni Corradini
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

Review 6.  Neoplastic disease after liver transplantation: Focus on de novo neoplasms.

Authors:  Patrizia Burra; Kryssia I Rodriguez-Castro
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

7.  Quantifying the Effect of Transplanting Older Donor Livers Into Younger Recipients: The Need for Donor-recipient Age Matching.

Authors:  Therese Bittermann; David S Goldberg
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

8.  Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Authors:  Antonio Ascione; Massimo De Luca; Mario Melazzini; Simona Montilla; Maria Paola Trotta; Salvatore Petta; Massimo Puoti; Vincenzo Sangiovanni; Vincenzo Messina; Savino Bruno; Antonio Izzi; Erica Villa; Alessio Aghemo; Anna Linda Zignego; Alessandra Orlandini; Luca Fontanella; Antonio Gasbarrini; Marco Marzioni; Edoardo G Giannini; Antonio Craxì
Journal:  Infection       Date:  2018-05-28       Impact factor: 7.455

9.  Antibody-mediated rejection after adult living-donor liver transplantation triggered by positive lymphocyte cross-match combination.

Authors:  Tomohide Hori; Hiroto Egawa; Shinji Uemoto
Journal:  Ann Gastroenterol       Date:  2012

Review 10.  Chronic HCV infection: epidemiological and clinical relevance.

Authors:  S Zaltron; A Spinetti; L Biasi; C Baiguera; F Castelli
Journal:  BMC Infect Dis       Date:  2012-11-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.